In this study, we aimed to analyze the results of stereotactic body radiotherapy (SBRT) in patients with adrenal gland metastasis due to different primary tumors.
METHODS
26 patients with 29 adrenal gland metastases who were treated between 2011-2018 with Cyberknife
Robotic System were evaluated retrospectively.
RESULTS
The origin of adrenal gland metastasis was lung in 22 patients, breast in 1 patient, parotid gland in 1
patient, and sarcoma in 2 patients. Fifteen patients (58 %) had other organ metastasis in addition to the
adrenal metastases. Six patients were treated for synchronous metastasis and 20 patients for metachronous
metastasis. SBRT was performed in median 3 fractions (3?5 fractions), and the median prescription
dose to PTV was 30 Gy (18- 45 Gy), with a BED10 (Biological Equivalent Dose) value of 60 Gy
(28.8-112,5 Gy). The median follow-up time was 11 months (1-34 months), and median overall survival
was 12 months after SBRT, 1,2-years survival rates were 49,7%, 21% respectively. Median time to local
failure was not reached, and the 6-months, 1 and 2-years local failure free survival rates were 78,6%,
66,5% and 66,5% respectively. The presence of metastatic disease outside the adrenal gland was found
to be a significant prognostic factor on survival after SBRT in both univariate and multivariate analyzes,
(HR:3; 95% CI 1,06-8,55 p:0,04). In general treatment was well tolerated and no major acute toxicities
were observed.
CONCLUSION
SBRT provides high local control rates and a well tolerated treatment in patients with adrenal gland
metastases. Survival is particularly encouraging for patients with solitary adrenal metastasis.